Gln 27?Glu? 2-adrenergic receptor polymorphism in heart failure patients: Differential clinical and oxidative response to carvedilol

Lavandero S.; Troncoso R.; Moraga, F; Chiong M.; Roldan, J; Bravo, R.; Valenzuela R.; Diaz-Araya, G; del Campo, A; Sanhueza C.; Rodríguez A.; Mellado R.; Vukasovic J.L.; greig d.; Castro P.F.

Keywords: oxidation, acid, heart, polymorphism, blood, disease, stress, trial, single, beta, physiology, metabolism, down-regulation, humans, human, male, genetics, receptor, failure, regulation, level, aged, carbazole, pathophysiology, agent, adult, female, glutamine, ejection, adrenergic, drug, antagonism, article, blocking, malondialdehyde, pharmacogenetics, carvedilol, function, fraction, genetic, chronic, ventricle, clinical, oxidative, beta-2, nucleotide, left, response, derivative, priority, middle, Rate, journal, Receptors,, 2, noradrenalin, effect, Ventricular, Adrenergic,, Polymorphism,, Function,, glutamic, down, beta-Antagonists, malonaldehyde, Propanolamines, Carbazoles, propanolamine


We investigated the clinical response of chronic heart failure patients with ? 2-adrenergic receptor Gln 27?Glu polymorphism treated for 6 months with carvedilol, a ?/?-antagonist with antioxidant properties. The 6-min. walk test, the left ventricular ejection fraction, heart rate, plasma norepinephrine and malondialdehyde, a stress oxidative marker, concentrations were evaluated at baseline and after treatment for 6 months with carvedilol in 33 stable chronic heart failure patients with the Gln 27?Glu? 2-adrenergic receptor polymorphism. Carvedilol significantly increased the left ventricular ejection fraction, while decreasing the heart rate and malondialdehyde plasma concentrations in chronic heart failure patients with the Glu 27? 2-adrenergic receptor allele. There were however, no significant changes in patients with the Gln 27? 2- adrenergic receptor variant. © 2009 Nordic Pharmacological Society.

Más información

Título de la Revista: Basic and Clinical Pharmacology and Toxicology
Volumen: 104
Número: 5
Editorial: Nordic Pharmacological Society
Fecha de publicación: 2009
Página de inicio: 374
Página final: 378